<DOC>
	<DOCNO>NCT00215826</DOCNO>
	<brief_summary>The purpose trial conduct randomize dose-ranging study evaluate safety activity orally administer low dose interferon alfa-n3 antiviral immunomodulator asymptomatic subject recent exposure person severe acute respiratory syndrome ( SARS ) possible SARS . The primary objective pilot study determine Alferon LDO dose level increase upregulates gene know mediator interferon response . Secondary endpoint include development SARS symptomatology , rate hospitalization , mortality rate . In event subject recent exposure person SARS possible SARS available , study conduct 10 normal volunteer .</brief_summary>
	<brief_title>Study Alferon® LDO ( Low Dose Oral ) Normal Volunteers</brief_title>
	<detailed_description>This study open-label , randomize , outpatient study subject potentially infect SARS-CoV ( SARS-associated coronavirus ) normal volunteer use two dose level LDO interferon . Subjects randomize receive Alferon® LDO ( natural interferon alfa-n3 ) buffer solution day 10 consecutive day dose equal 650 IU 1300 IU/day . Pretherapy baseline evaluation perform prior randomization . Subjects randomly assign dose level , dosage level start concurrently . Drug dispense ten day treatment period , time clinical symptom adverse event evaluate . Laboratory sample ( 2.5 ml blood ) microarray analysis evaluation make twice baseline 12-14 hour follow dos 1 , 5 , 10 study day 2 , 6 , 11 , respectively . The conduct study comply International Conference Harmonisation - Good Clinical Practice ( ICH - GCP ) 1996 late version Declaration Helsinki .</detailed_description>
	<mesh_term>Severe Acute Respiratory Syndrome</mesh_term>
	<mesh_term>Coronavirus Infections</mesh_term>
	<mesh_term>Interferons</mesh_term>
	<mesh_term>Interferon-alpha</mesh_term>
	<criteria>1 . 1880 year age . 2 . Asymptomatic close contact within last 5 day person know possible SARS ( SARS RUI2 ( SARS Report investigation ) , RUI3 , RUI4 ) probable SARS confirm SARS use Centers Disease Control Prevention ( CDC ) Supplement B : SARS Surveillance , Appendix B1 : Revised Council State Territorial Epidemiologists ( CSTE ) SARS Surveillance Case Definition ( Attachment II ) . 3 . Oral temperature &lt; 100.4°F ( &lt; 38°C ) 4 . Subjects must asymptomatic regard SARS relate clinical symptom include sign respiratory illness . 5 . Serum creatinine ≤ 1.5 x ULN ( upper limit normal ) ; serum bilirubin ≤ 1.5 x ULN . 6 . Total white blood cell ( WBC ) ≥ 3000/mm3 , platelet count ≥ 100,000/mm3 granulocyte ≥ 1500 mm3 . 7 . Hemoglobin &gt; 10.0 g/dl . 8 . ALT ( alanine aminotransferase ) AST ( aspartate aminotransferase ) &lt; 4 time upper normal limit . 9 . Creactive protein serum level normal range 10 . Serum albumin &gt; 2.0 g/dl . 11 . Written informed consent . 12 . Females must either nonchild bear potential , utilize effective form contraception negative pregnancy test prior randomization . 1 . Pregnant nursing woman , woman use effective form contraception . 2 . Less 18 year age . 3 . Active intravenous ( IV ) drug user . 4 . Receipt immunosuppressive agent , chemotherapy , systemic steroid within 45 day study entry . 5 . Receipt immunomodulator BCG ( bacille Calmette Guerin ) vaccine , isoprinosine , similar experimental agent within 45 day study entry . 6 . Evidence HIV viral infection include chronic hepatitis , active gastrointestinal , renal , respiratory , endocrine , hematologic , cardiovascular , neurological , psychiatric disorder would limit subject 's ability complete study period . 7 . Unlikely unable comply requirement protocol . 8 . Patients unwilling unable give inform consent . 9 . Patients concurrent experimental medication . 10 . Patients use form interferon therapy 6 week prior study entry . 11 . Hospitalized subject , active viral infection possible SARS , within 2 week study entry . 12 . Transfusion dependent subject ( subject require &gt; 1 unit pack RBC [ red blood cell ] per month within 3 month prior study entry ) .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>April 2013</verification_date>
	<keyword>SARS</keyword>
	<keyword>Alferon LDO</keyword>
	<keyword>Low Dose Oral Interferon ALFA-n3</keyword>
	<keyword>Human Leukocyte Derived</keyword>
	<keyword>Exposure SARS</keyword>
	<keyword>Possible SARS</keyword>
</DOC>